Stocksigma LogoStocksigma Logo

Mankind Pharma Q2 FY27 Financial Results and Corporate Restructuring Summary

Mankind Pharma reported consolidated revenue from operations of ₹4,337.86 Cr for the quarter ended 30th Sep'26, up 17.33% YoY from ₹3,697.16 Cr

Mankind Pharma Q2 FY27 Financial Results and Corporate Restructuring Summary

Mankind Pharma Ltd · Others (Uncategorized) · 26 Oct 2026, 8:47 pm

Mankind Pharma Q2 FY27 Financial Results and Corporate Restructuring Summary Mankind Pharma reported consolidated revenue from operations of ₹4,337.86 Cr for the quarter ended 30th Sep'26, up 17.33% YoY from ₹3,697.16 Cr. Consolidated net profit rose 37.67% YoY to ₹716.12 Cr compared to ₹520.18 Cr. For H1 FY27, consolidated revenue reached ₹8,368.45 Cr with net profit at ₹1,290.21 Cr. The Board approved the merger of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma with an appointed date of 1st Apr'27, involving no share issuance or cash outflow.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements